Sonoma Pharmaceuticals Q2 revenue beats expectations on increased distributor sales

Sonoma Pharmaceuticals

04/11/2025 14:04

Overview

Sonoma fiscal Q2 revenue grows 57% yr/yr, beating analyst expectations

Net loss per share decreases 46% for fiscal Q2 compared to last year

U.S. revenue increases 115% for fiscal Q2, driven by OTC product sales

Outlook

Company expects positive growth trajectory with increasing product adoption

Result Drivers

U.S. SALES GROWTH - Revenue in the U.S. increased 115% due to higher sales of OTC products and increased distributor sales

NEW PRODUCT LAUNCHES - Launch of HOCl-based diaper rash products and other new products contributed to revenue growth

REGULATORY MILESTONES - Key regulatory clearances, including FDA registration, supported growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$5.60 mln
$4.26 mln (1 Analyst)
Q2 EPS
-$0.32
Q2 Net Income
-$500,000
Q2 EBITDA
-$200,000
Q2 Gross Profit
$2.10 mln
Q2 Operating Expenses
$2.50 mln


Analyst Coverage

The one available analyst rating on the shares is "strong buy"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Sonoma Pharmaceuticals Inc is $14.80, about 74.5% above its November 3 closing price of $3.78

Press Release: ID:nACSQC7GQa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)